Back to search results

Ultra-Low Field MRI for Brain Conditions

This study is looking at a new type of MRI called Ultra-Low Field (ULF) MRI. MRI (Magnetic Resonance Imaging) is a way to take pictures inside your body and brain. The goal is to see if ULF-MRI can find brain problems (like stroke or epilepsy) as well as the standard MRI. This new ULF-MRI system could be used in a mobile unit, making it easier for more people to get brain scans. Researchers want to understand how well ULF-MRI works to help more people get diagnosed and treated for nervous system diseases. You can join if you are 3 years or older and have or show symptoms of a neurological disease. The study aims to enroll 200 participants.

Study design
This is an observational study, meaning researchers will collect information without giving any specific treatment. It plans to enroll 200 participants.
What's involved
You would need to be willing to follow all study procedures and be available for the study's duration. You will have a ULF-MRI scan at Visit 1, and potentially an optional second visit within 180 days.
Compensation
Not stated in the trial record.
Follow-up
Your ULF-MRI sensitivity will be measured at Visit 1 and an optional visit two within 180 days. Technical development will be measured at Visit 1 and optional repeated visits through the life of the protocol.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06203626

Ultra-Low Field (ULF) Point-of-Care (POC) MRI System for Brain Morphology and Pathology

Recruiting
Not specifiedAges 3–99Observational
National Institute of Neurological Disorders and Stroke (NINDS)
~200 participants
Updated 2026-08-07 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
ULF-MRI sensitivity to detect presence of pathology
Measured over Visit 1 and optional visit two within 180 days.
+1 more outcome measured

Conditions

Nervous System Diseases (C10 Unique ID D009422)

Explore related trials

Malignant Brain NeoplasmNervous System DisorderSeizure DisorderStroke

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Silvina G Horovitz, Ph.D. · PRINCIPAL_INVESTIGATOR · National Institute of Neurological Disorders and Stroke (NINDS)

Who to contact

Ruli Zhang
[email protected]
(301) 435-6028
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Stated willingness to comply with all study procedures and availability for the duration of the study.
Volunteer of any gender, 3 years of age and older.
Adult participant: must be capable of understanding the procedures and requirements of this study and be able and willing to sign an informed consent document.
Minor participant: Must have a parent or guardian capable of understanding the procedures and requirements of this study who are willing to sign an informed parental consent document, and where feasible, the minor age 7 and older provides assent.
Either:
Adult in good general health as evidenced by medical history or
Diagnosed with a stroke, a neurological or neuro-oncological disease, or
Exhibiting symptoms suggestive of neurological or neuro-oncological disease.

Exclusion

Unable to undergo MRI study based on screening (e.g., presence of non-MRI compatible objects).
Pregnancy or lactation, if contrast agent is required.

What this trial measures

  • ULF-MRI sensitivity to detect presence of pathologyVisit 1 and optional visit two within 180 days.

    ULF-MRI sensitivity to detect presence of pathology in comparison to the standard field MRI measured in 100 cases. A study will be considered to have a positive finding if the clinical report from the MRI brain collected at standard field has an observation.

  • Technical developmentVisit 1 and optional repeated visits through the life of the protocol.

    Optimization of acquisition parameters, reproducibility, and training of personnel.